Companies: 10,795·Total market cap: $144.5T
Ibere Pharmaceuticals

Ibere Pharmaceuticals

IBERNYSEFinancial Services
$10.18
$-0.03(-0.29%)
Market Cap$175605000
P/E Ratio—
52W High$10.75
52W Low$9.75
SEC Filings

Ibere Pharmaceuticals (IBER) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001835205 · IBER · NYSE · as of Jun 8, 2026

Filing snapshot

51
Total Filings
15-12G
Latest Form
2023-03-13
Most Recent
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001835205 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2022-03-31
Fiscal Year End
Mar 31, 2022
Accession No.
0001410578-22-000776
Primary Document
tmb-20211231x10k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001835205 · Accession 0001410578-22-000776

Latest Key Filings

10-QQuarterly Report
10-Q
2022-11-14
View 10-Q on SEC
8-KCurrent Report
FORM 8-K
2023-02-15Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
15-12G15-12G
15-12G
2023-03-13
View
25-NSE25-NSE
25-NSE
2023-03-02
View
8-KCurrent Report
FORM 8-K
2023-02-15
View
SC 13GBeneficial Ownership Report
Beneficial Ownership Report
2023-02-14
View
SC 13G/ABeneficial Ownership Report (Amended)
SC 13G/A
2023-02-14
View
SC 13GBeneficial Ownership Report
IBER 13G
2023-02-08
View
SC 13G/ABeneficial Ownership Report (Amended)
SCHEDULE 13G (AMENDMENT NO. 1)
2023-02-08
View
SC 13G/ABeneficial Ownership Report (Amended)
SC 13G/A
2023-02-02
View
10-QQuarterly Report
10-Q
2022-11-14
View
10-QQuarterly Report
10-Q
2022-08-12
View
10-QQuarterly Report
10-Q
2022-05-16
View
10-KAnnual Report
10-K
2022-03-31
View
SC 13G/ABeneficial Ownership Report (Amended)
IBERE PHARMACEUTICALS
2022-02-14
View
SC 13GBeneficial Ownership Report
SC 13G
2022-02-08
View
SC 13GBeneficial Ownership Report
SCHEDULE 13G
2022-01-14
View
Showing 1–15 of 50 filingsForm 4 / 144 hidden· 51 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001835205  |  Exchange: NYSE · Financial Services

Ibere Pharmaceuticals (NYSE: IBER) has submitted 51 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in . As a Financial Services sector company with CIK 0001835205, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Ibere Pharmaceuticals's most comprehensive regulatory disclosure. The most recent Ibere Pharmaceuticals 10-K was filed on 2022-03-31 for fiscal year ending 2022. Historical IBER 10-K annual reports are available from 2020 through 2022.

Investors researching Ibere Pharmaceuticals SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Financial Services
VACQ SEC Filings →SLAM SEC Filings →TRIS SEC Filings →BTWN SEC Filings →APCA SEC Filings →PRBM SEC Filings →FSNB SEC Filings →LCW SEC Filings →
→ IBER Financials→ IBER Earnings→ IBER Insider Trades

Frequently Asked Questions

IBER SEC Filings · 8 questions

Ibere Pharmaceuticals (IBER) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 51 filings and access original documents at no cost. Ibere Pharmaceuticals's CIK is 0001835205.

IBER SEC filingsIbere Pharmaceuticals SEC documentsfind IBER 10-K